Cel Sci (CVM) Research & Development (2010 - 2026)
Cel Sci (CVM) posted Research & Development of $3.8 million for Q1 2026, up 2.44% sequentially from $3.7 million in Q4 2025, and down 6.16% YoY from $4.0 million in Q1 2025.
Cel Sci (CVM) Research & Development (2010 - 2026) Analysis & Trends
Cel Sci has reported Research & Development for 15 years, with the latest figure at $3.8 million in Q1 2026.
- Quarterly Research & Development fell 6.16% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (down 15.53% YoY) and the FY2025 annual result came in at $15.9 million, down 12.52% from the prior year.
- Research & Development advanced to $3.8 million in Q1 2026 per CVM's latest filing, from $3.7 million in the prior quarter.
- Over five years, Research & Development peaked at $6.5 million in Q1 2022 and troughed at $3.7 million in Q4 2025.
- A 5-year average of $4.9 million and a median of $4.6 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2024: Research & Development gained 24.94% in 2022, then slipped 23.92% in 2024.
- Over 5 years, Research & Development stood at $5.4 million in 2022, then retreated by 19.29% to $4.4 million in 2023, then advanced by 1.78% to $4.4 million in 2024, then retreated by 16.99% to $3.7 million in 2025, then grew by 2.44% to $3.8 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $3.8 million, $3.7 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Cel Sci | 2.16 Mn | -4.37 Mn | - | 3.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.77 Mn |
| Dec 31, 2025 | 3.68 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | 3.74 Mn |
| Mar 31, 2025 | 4.01 Mn |
| Dec 31, 2024 | 4.43 Mn |
| Sep 30, 2024 | 4.48 Mn |
| Jun 30, 2024 | 4.70 Mn |
| Mar 31, 2024 | 4.63 Mn |
| Dec 31, 2023 | 4.35 Mn |
| Sep 30, 2023 | 5.27 Mn |
| Jun 30, 2023 | 5.73 Mn |
| Mar 31, 2023 | 6.08 Mn |
| Dec 31, 2022 | 5.39 Mn |
| Sep 30, 2022 | 6.46 Mn |
| Jun 30, 2022 | 6.29 Mn |
| Mar 31, 2022 | 6.52 Mn |
| Dec 31, 2021 | 6.08 Mn |
| Sep 30, 2021 | 5.29 Mn |
| Jun 30, 2021 | 7.18 Mn |